chevron_leftBack
As of 24 April 2025, Granules India Ltd. has a market cap of $1.37B USD, ranking #6827 globally and #466 in India. It ranks #656 in the Healthcare sector, and #143 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$1.37BUSD
116.48B INR
Enterprise Value
$1.47BUSD
125.29B INR
Revenue (TTM)
$522.67MUSD
44.6B INR
EBITDA (TTM)
$110.79MUSD
9.47B INR
Net Income (TTM)
$56.15MUSD
4.79B INR
EBITDA Margin
21%
Profit Margin
11%
PE Ratio
24.3
Company Profile
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1% | 6.4% | -5.4% | -19% | -19% | 17% |
Upcoming Earnings
Earnings Date
Fri, May 16
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
GRANULES
Granules India Ltd
ISIN: INE101D01020
Shares Out.:
Shares Outstanding:
242.544M1
Shares Float:
145.093M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
484.95 INR | |
|
532482
(GRANULES)
Granules India Ltd
ISIN: INE101D01020
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
467.40 INR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Granules India Ltd.
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. In addition, the company provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. Granules India Limited was founded in 1984 and is based in Hyderabad, India.
